tetano
Editor, Senior Moderator
Int J Infect Dis
. 2020 May 29;S1201-9712(20)30392-1.
doi: 10.1016/j.ijid.2020.05.085. Online ahead of print.
Lack of Antiviral Activity of Darunavir Against SARS-CoV-2
Sandra De Meyer[SUP] 1 [/SUP], Denisa Bojkova[SUP] 2 [/SUP], Jindrich Cinatl[SUP] 2 [/SUP], Ellen Van Damme[SUP] 3 [/SUP], Christophe Buyck Meng[SUP] 3 [/SUP], Marnix Van Loock[SUP] 3 [/SUP], Brian Woodfall[SUP] 4 [/SUP], Sandra Ciesek[SUP] 5 [/SUP]
Affiliations
Abstract
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives.
Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed.
Results: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC[SUB]50[/SUB] >100μM). Remdesivir, used as a positive control, showed potent antiviral activity (EC[SUB]50[/SUB]=0.38μM).
Conclusions: Overall, the data do not support the use of DRV for treatment of COVID-19.
Keywords: COVID-19; Darunavir; SARS-CoV-2; in vitro.
. 2020 May 29;S1201-9712(20)30392-1.
doi: 10.1016/j.ijid.2020.05.085. Online ahead of print.
Lack of Antiviral Activity of Darunavir Against SARS-CoV-2
Sandra De Meyer[SUP] 1 [/SUP], Denisa Bojkova[SUP] 2 [/SUP], Jindrich Cinatl[SUP] 2 [/SUP], Ellen Van Damme[SUP] 3 [/SUP], Christophe Buyck Meng[SUP] 3 [/SUP], Marnix Van Loock[SUP] 3 [/SUP], Brian Woodfall[SUP] 4 [/SUP], Sandra Ciesek[SUP] 5 [/SUP]
Affiliations
- PMID: 32479865
- DOI: 10.1016/j.ijid.2020.05.085
Abstract
Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives.
Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800mg of the HIV protease inhibitor darunavir (DRV) and 150mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed.
Results: DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC[SUB]50[/SUB] >100μM). Remdesivir, used as a positive control, showed potent antiviral activity (EC[SUB]50[/SUB]=0.38μM).
Conclusions: Overall, the data do not support the use of DRV for treatment of COVID-19.
Keywords: COVID-19; Darunavir; SARS-CoV-2; in vitro.